ONCOZEN

menu closed

business field

company identity

ONCOZEN is More experienced, More creative, more expeditious

ONCOZEN

BIOTECH

Research &
Development

Develop New Anti-Cancer Drug (FIRST-IN-CLASS & BEST-IN-CLASS): New molecule of Novel Dual Action; New molecule for Novel Target

Focus on Mega-sized Market for Cancer therapeutics & Orphan Drug Market

Platform
Technology

CMPD (Chaperone-Mediated Protein Degradation) Platform Technology: Novel Modality for Target Protein Degradation

Extensibility for Indication: Targeted degradation of “Undruggable Disease-causing Protein” for Cancer/Rare Disease

Available to Design an Expansive & Diversity Pipeline

Business
Development

Open Innovation Strategy: Differentiation in selection of Asset

Professional Manpower for Research / Business Development: Availability of out-licensing business in early stage & co-development

Know-how to conduct Project: Expeditious Development Strategy, High Return Strategy

Business Development Strategy

For strategic EXIT, we share client needs to select items.
Increase project value with differentiated strategies, internal know-how
and solutions with MINIMUM RISK.

Human Resources from R&D of
Pharmaceutical Companies

New Drug Development Know-how in Korea and abroad
* Providing Consulting Service for Drug development
& Regulatory Affairs on the basis of
Accumulated Experience & Pool

Development Progress Speed Up

Leverage external R&D infrastructure
Utilization of infrastructure such as authorized
institutions/research institutions (CMC/CRO)

Experience Various Exit Strategies

→ Securing L/O, L/I, and Co-development strategies
Excellent Domestic Pharmaceutical/Bio-human Network
Overseas Local Deal Connection → Short Term Biz Strengths